Semper Paratus Acquisition's (TVGN) "Buy" Rating Reaffirmed at D. Boral Capital

Semper Paratus Acquisition (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $10.00 price target on the stock.

Semper Paratus Acquisition Stock Performance

Shares of NASDAQ TVGN opened at $1.21 on Wednesday. The firm has a 50 day moving average of $1.14 and a 200 day moving average of $1.20. Semper Paratus Acquisition has a 12-month low of $0.26 and a 12-month high of $3.09.

Insider Activity

In other news, CEO Ryan H. Saadi sold 1,438,206 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $1.23, for a total transaction of $1,768,993.38. Following the transaction, the chief executive officer now owns 116,814,453 shares of the company's stock, valued at approximately $143,681,777.19. The trade was a 1.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 73.24% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Barclays PLC increased its position in shares of Semper Paratus Acquisition by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after acquiring an additional 12,847 shares during the period. Northern Trust Corp lifted its holdings in shares of Semper Paratus Acquisition by 13.0% in the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after buying an additional 13,595 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Semper Paratus Acquisition by 74.2% in the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after acquiring an additional 16,695 shares in the last quarter. XTX Topco Ltd purchased a new stake in Semper Paratus Acquisition in the fourth quarter worth about $55,000. Finally, Nuveen LLC bought a new position in Semper Paratus Acquisition during the 1st quarter worth about $97,000.

About Semper Paratus Acquisition

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.